| Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer (NCT02245100) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-07-22 |
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02035527) | Ohio State University Comprehensive Cancer Center | 2014-04-14 |
| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (NCT02123511) | Mayo Clinic | 2014-04-01 |
| Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy (NCT01728480) | Roswell Park Cancer Institute | 2014-01-01 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection (NCT01249443) | AIDS Malignancy Consortium | 2013-11-01 |
| Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy (NCT01674374) | Roswell Park Cancer Institute | 2013-05-01 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT01816984) | University of Chicago | 2013-05-01 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (NCT01528137) | Stanford University | 2012-05-01 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT01349933) | National Cancer Institute (NCI) | 2011-04-01 |
| Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer (NCT01254734) | City of Hope Medical Center | 2011-04-01 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (NCT01316757) | Fox Chase Cancer Center | 2011-02-16 |
| Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck (NCT01192815) | Case Comprehensive Cancer Center | 2011-01-01 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer (NCT01155609) | University of Washington | 2010-09-01 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (NCT00939627) | National Cancer Institute (NCI) | 2009-07-01 |
| Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (NCT01682031) | Roswell Park Cancer Institute | 2009-06-01 |
| Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy (NCT00895245) | University of Washington | 2009-02-01 |
| Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) (NCT00896181) | Stanford University | 2008-12-10 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (NCT01637194) | Fox Chase Cancer Center | 2008-11-01 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT00906360) | National Cancer Institute (NCI) | 2008-07-01 |
| Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. (NCT01469429) | Ohio State University Comprehensive Cancer Center | 2007-09-04 |
| Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer (NCT00454142) | National Cancer Institute (NCI) | 2007-08-01 |
| Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00513435) | National Cancer Institute (NCI) | 2007-07-01 |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00507767) | National Cancer Institute (NCI) | 2007-07-01 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (NCT00492089) | National Cancer Institute (NCI) | 2007-06-01 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (NCT00397384) | National Cancer Institute (NCI) | 2007-01-01 |
| Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (NCT00387335) | National Cancer Institute (NCI) | 2006-08-01 |
| Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer (NCT00410826) | University of Washington | 2006-06-01 |
| Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT00103259) | National Cancer Institute (NCI) | 2005-07-01 |
| Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer (NCT00114283) | National Cancer Institute (NCI) | 2005-03-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00096512) | National Cancer Institute (NCI) | 2004-10-01 |
| Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (NCT00098631) | National Cancer Institute (NCI) | 2004-10-01 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00089362) | National Cancer Institute (NCI) | 2004-07-01 |
| Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck (NCT00081211) | National Cancer Institute (NCI) | 2004-04-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck (NCT00063895) | National Cancer Institute (NCI) | 2003-04-01 |
| Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00055913) | National Cancer Institute (NCI) | 2003-03-01 |
| Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer (NCT00055770) | National Cancer Institute (NCI) | 2002-10-01 |
| Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer (NCT00049283) | National Cancer Institute (NCI) | 2002-09-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (NCT00023959) | National Cancer Institute (NCI) | 2001-07-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |